Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 12 September 2017

Indication(s)

Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Obesity

Obesity

Learn about the complex factors influencing development of obesity.

+ 4 more

ALP Lab Assessment

ALP Lab Assessment

Discover and overview of hypophosphatasia and details required to facilitate the timely and accurate detection of low alkaline phosphatase.

Fabry Disease

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000854
Orphan designation No
Date First Approved 23-07-2007
Type Medicinal product not subject to medical prescription
Marketing authorisation holder Glaxo Group Ltd.